)
Aurobindo Pharma Limited reported over four-fold increase in consolidated net profit at Rs 416.12 crore for the quarter ended December, 2013, on the back of improved sales and margins on account of new launches in the US. Net profit for the same quarter in the previous year was Rs 91 crore.
Total income rose 36 per cent to Rs 2,144.12 crore as compared with Rs 1,575.73 crore in the corresponding quarter previous year while the expenditure went up 14.64 per cent to Rs 1,572.73 crore from Rs 1,371.79 crore in the year ago period, indicating an upside in sales revenues.
"We have had a robust quarter driven by our sustaining base business along with successful launches in the US, translating into better top and bottom line . We are confident to sustain the momentum as we foray into strengthening our access into markets, products and technology platforms where we are not dominantly present as we consolidate on our existing businesses," sad N Govindarajan, managing director of Aurobindo.
The formulations sales in the US saw an 81.4 per cent jump at Rs 931.2 crore in the quarter under review from Rs 513.4 crore in the year ago period.
